Lavanya Bellumkonda, MD
Associate Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2025
Diagnosis and management of cardiogenic shock.
Bellumkonda L. Diagnosis and management of cardiogenic shock. Current Opinion In Critical Care 2025 PMID: 40552838, DOI: 10.1097/mcc.0000000000001288.Peer-Reviewed Original ResearchCardiogenic shockLong-term outcomes of patientsOutcomes of patientsMultidisciplinary team-based approachLong-term outcomesManagement of cardiogenic shockAcute myocardial infarctionOverall prognosisStages of shockInfluence prognosisAggressive managementPoor prognosisRisk stratificationImprove mortalityTreatment strategiesTeam-based approachPhenotypic presentationMyocardial infarctionPrognosisClinical practiceEscalate careDisease processEarly identificationRefining interventionsPatientsSCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women This statement was endorsed by the Heart Failure Society of America (HFSA)
Baron S, Chou J, Shah T, Vest A, Abbott J, Alasnag M, Aurigemma C, Barbato E, Bellumkonda L, Bortnick A, Chieffo A, van Geuns R, Grines C, Halvorsen S, Hassager C, Kapur N, Naidu S, Ng V, Saw J, Lansky A. SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women This statement was endorsed by the Heart Failure Society of America (HFSA). Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102150. DOI: 10.1016/j.jscai.2024.102150.Peer-Reviewed Original ResearchHeart Failure Society of AmericaCardiogenic shockWomen's cardiovascular healthConsensus statementSex-based disparitiesExpert consensus statementCardiovascular healthCardiovascular disease statesTreatment of CSTreatment of womenCardiovascular diseasePoor outcomeWomenDisparitiesSociety of AmericaDisease statesCS treatmentTreatmentPracticeHealthClinicians71987 | Readmission Reduction in the Structural Heart Population Using Risk Stratification and Targeted Interventions
Todice M, Forrest J, Bellumkonda L, Workiewicz A, Levesque L, McManus S. 71987 | Readmission Reduction in the Structural Heart Population Using Risk Stratification and Targeted Interventions. Structural Heart 2025, 9: 100518. DOI: 10.1016/j.shj.2025.100518.Peer-Reviewed Original ResearchSCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women.
Baron S, Chou J, Shah T, Vest A, Abbott J, Alasnag M, Aurigemma C, Barbato E, Bellumkonda L, Bortnick A, Chieffo A, van Geuns R, Grines C, Halvorsen S, Hassager C, Kapur N, Naidu S, Ng V, Saw J, Lansky A. SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women. EuroIntervention 2025 PMID: 40387531, DOI: 10.4244/eij-d-24-01126.Peer-Reviewed Original ResearchWomen's cardiovascular healthCardiogenic shockConsensus statementSex-based disparitiesCardiovascular healthExpert consensus statementCardiovascular disease statesTreatment of CSCardiovascular diseaseTreatment of womenWomenPoor outcomeDisparitiesDisease statesCS treatmentTreatmentPracticeHealthCliniciansPractical Guide on the Use of Induction Immunosuppression in Heart Transplantation.
Nikolova A, Bellumkonda L, Bhardwaj A, Fida N, Holzhauser L, Umapathi P, De Marco T, Contreras J. Practical Guide on the Use of Induction Immunosuppression in Heart Transplantation. Circulation Heart Failure 2025, e012382. PMID: 40371476, DOI: 10.1161/circheartfailure.124.012382.Peer-Reviewed Original ResearchInduction immunosuppressionHeart transplantationImpact of induction immunosuppressionHepatitis C positivityRenal protective strategiesRisk stratification modelAt-risk patientsInduction therapyInduction regimensCirculatory death donorsMalignant complicationsMechanical circulatory devicesPerioperative periodImmunomodulatory effectsRecipient riskImmunosuppressionDeath donorsStratification modelTransplantationTherapyPatientsCirculatory devicesAt-riskInductionRIGHT AND LEFT VENTRICULAR REMODELING AFTER ATRIAL SEPTAL DEFECT CLOSURE
Saleh A, Bellumkonda L, Rizzo M, Heller D, Francese D, Tirziu D, Lansky A, Sugeng L, Karnik R. RIGHT AND LEFT VENTRICULAR REMODELING AFTER ATRIAL SEPTAL DEFECT CLOSURE. Journal Of The American College Of Cardiology 2025, 85: 759. DOI: 10.1016/s0735-1097(25)01243-4.Peer-Reviewed Original ResearchEffect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis
Shah T, Zhang Z, Shah H, Fanaroff A, Nathan A, Parise H, Lutz J, Sugeng L, Bellumkonda L, Redfors B, Omerovic E, Petrie M, Vora A, Fiorilli P, Kobayashi T, Ahmad Y, Forrest J, Giri J, Herrmann H, Lansky A. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC Cardiovascular Interventions 2025, 18: 738-748. PMID: 39985508, DOI: 10.1016/j.jcin.2024.11.036.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsCotransporter-2 inhibitorsAortic stenosisEffects of sodium-glucose cotransporter-2 inhibitorsProgression of aortic stenosisBaseline AS severityAssociated with slower progressionEchocardiographic follow-upRetrospective electronic medical record dataAortic valve sclerosisDisease-related morbidityChronic kidney diseaseSGLT2i usageRates of diabetesSevere ASAS severityEjection fractionFollow-upPrimary outcomeGt;1 yearKidney diseaseMedical record dataYale New Haven Health SystemPatientsObservational studyElevated Systolic Blood Pressure and Hemodynamic Parameters in Patients With Aortic Stenosis Undergoing Echocardiography in Real-World Practice
Singh J, Reinhardt S, Hur D, Sugeng L, Akintoye E, Lombo B, Bellumkonda L, Shkolnik E, McNamara R, Faridi K. Elevated Systolic Blood Pressure and Hemodynamic Parameters in Patients With Aortic Stenosis Undergoing Echocardiography in Real-World Practice. Journal Of The American Society Of Echocardiography 2025, 38: 509-511. PMID: 39884444, DOI: 10.1016/j.echo.2025.01.010.Peer-Reviewed Original Research
2024
Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella
Rommel K, Bonnet G, Bellumkonda L, Lansky A, Zhao D, Thompson J, Zhang Y, Redfors B, Lurz P, Granada J, Bharadwaj A, Basir M, O'Neill W, Burkhoff D. Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella. Journal Of Cardiac Failure 2024, 30: 1244-1254. PMID: 39389734, DOI: 10.1016/j.cardfail.2024.08.001.Peer-Reviewed Original ResearchConceptsRight ventricular dysfunctionHigh-risk percutaneous coronary interventionVentricular dysfunctionAssociated with right ventricular dysfunctionTricuspid annular plane systolic excursionConcomitant right ventricular dysfunctionLower left ventricular ejection fractionUnfavorable long-term prognosisAnnular plane systolic excursionClinical outcomes of patientsAbsence of right ventricular dysfunctionImpella supportPredictor of 1-year mortalityMultivariate Cox regression analysisIncidence of hypotensive episodesEchocardiography core laboratorySevere RV dilatationBlood urea nitrogen levelsRV function assessmentVentricular ejection fractionOutcomes of patientsRates of in-hospital mortalityHigher blood urea nitrogen levelsLong-term prognosisProportion of patientsClinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI
Abu-Much A, Grines C, Chen S, Batchelor W, Zhao D, Falah B, Maini A, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Zhang Y, Zhou Z, Baron S, Lansky A, Basir M, O'Neill W, Cohen D. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI. International Journal Of Cardiology 2024, 417: 132555. PMID: 39270940, DOI: 10.1016/j.ijcard.2024.132555.Peer-Reviewed Original ResearchLower left ventricular ejection fractionMitral valve regurgitationPercutaneous coronary interventionHigh-risk PCISevere MRHigh-risk percutaneous coronary interventionMR severityPCI-related complicationsValve regurgitationIII studiesHeart failureAssociated with worse outcomesPrevalence of heart failurePresence of severe MRLower body mass indexVentricular ejection fractionStatistical significanceHigh-risk PCI patientsBody mass indexTrace MREjection fractionModerate MRClinical outcomesMild MRWorse outcomes
Clinical Trials
Current Trials
MitraClip REPAIR MR Study
HIC ID2000031013RoleSub InvestigatorPrimary Completion Date02/28/2024Recruiting ParticipantsGenderBothAge18+ yearsRandomized Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
HIC ID2000028335RolePrincipal InvestigatorPrimary Completion Date01/27/2025Recruiting ParticipantsGenderBothAge18+ yearsErtugliflozin in Acute Heart Failure
HIC ID2000027951RoleSub InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18+ yearsTranscatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation (APOLLO)
HIC ID2000021883RoleSub InvestigatorPrimary Completion Date10/31/2021Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Clinical Care
Overview
As a cardiologist who specializes in advanced heart failure and transplantation, Lavanya Bellumkonda, MD, says offering hope is key when she first meets a patient.
“When someone hears the term ‘heart failure,’ they may think they are dying imminently. I first review the severity of their disease and try to set realistic expectations. A number of patients with heart failure will have improvement in their cardiac function with appropriate medical therapy,” she explains. “If their disease is advanced, they may need a mechanical pump to assist the heart or a heart transplantation, and we discuss the success rates and risks associated with each of these strategies.”
Heart failure describes any kind of dysfunction in the heart that causes a build-up of fluids, resulting in shortness of breath, fatigue, and swelling in the legs. Dr. Bellumkonda says she was drawn to her field because of her fascination with the physiology of the heart and the acuity of cardiac illnesses.
“What I also like about transplant cardiology is that you get to apply all that you learnt in medicine and cardiology,” she says. “Post-transplant, patients often rely on me to manage their medical conditions as well.”
Additionally, Dr. Bellumkonda treats patients with valve disease. “The most common valves affected are the mitral or aortic valves, where these valves get either too tight or too leaky, causing symptoms similar to heart failure,” she says. “At Yale, we treat these patients in a multidisciplinary fashion and provide appropriate recommendations regarding catheter-based interventions and surgery.”
Her research interests include cardiac recovery and cardio-renal reactions in patients with valve disease. “What makes me most happy in my work is when I have cardiac recovery in my patients, meaning they have an improvement in their heart function,” she says. “That makes me feel like I have done my job.”
Clinical Specialties
Fact Sheets
Ventricular Assist Device (VAD)
Learn More on Yale MedicineCongestive Heart Failure (CHF)
Learn More on Yale MedicineExtracorporeal Membrane Oxygenation (ECMO)
Learn More on Yale MedicineHeart Failure Surgery
Learn More on Yale Medicine
Yale Medicine News
News & Links
News
Get In Touch
Contacts
Cardiovascular Medicine
333 Cedar St., PO Box 20817
New Haven, CT 06520
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.